A review of the use of exemestane in early breast cancer

References

• ParkinDBrayFFerlayJPisaniPGlobal Cancer Statistics, 2002CA Cancer J Clin2005557410815761078
   PubMed Web of Science ®Google Scholar
• JoslynSAHormone receptors in breast cancer: racial differences in distribution and survivalBreast Cancer Res Treat200273455912083631
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet20053651687171715894097
   PubMed Web of Science ®Google Scholar
• BeatsonGWOn the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative casesLancet18961483802104107
   Google Scholar
• HugginsCDaoTLAdrenalectomy and oophorectomy in treatment of advanced carcinoma of the breastJAMA195315113881394
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJA randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancerN Engl J Med20043501081109215014181
   PubMed Web of Science ®Google Scholar
• ZilemboNNoberascoCBajettaEMartinettiAMarianiLOreficiSEndocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitorBr J Cancer199572100710127547212
   PubMed Web of Science ®Google Scholar
• SpinelliRJannuzzoMGPoggesiIFrevolaLBroutinFCicioniPPharmacokinetics (PK) of Aromasin (Exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV)Eur J Cancer199935suppl 4S295
   Web of Science ®Google Scholar
• AnonymousExemestane for advanced breast cancerMed Lett Drugs Ther200042353610803175
   PubMed Web of Science ®Google Scholar
• DixonJMGrattageLRenshawLMillerWRExemestane as neoadjuvant treatment for locally advanced breast cancer: endocrinologic and clinical endpointsBreast Cancer Res Treat20006453
   Google Scholar
• JannuzzoMDi SalleESpinelliREstrogen suppression in pre-menopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin aloneBreast Cancer Res Treat2008 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• CoombesRCKilburnLSSnowdonCFSurvival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialLancet2007369956155917307102
   PubMed Web of Science ®Google Scholar
• JonesSEExemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trialsClin Breast Cancer20066suppl 2S41S4416595025
   PubMedGoogle Scholar
• MamounasEPJeongJ-HWickerhamDLBenefit from exemestane as extended adjuvant therapy following five years of adjuvant tamoxifen: Intent-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 TrialJ Clin Oncol2008261965197118332472
   PubMed Web of Science ®Google Scholar
• DellapasquaSColleoniMGelberRGoldhirshAAdjuvant endocrine therapy for premenopausal women with early breast cancerJ Clin Oncol2005261736175015755982
   PubMed Web of Science ®Google Scholar
• TakeiHSuemasuKInoueKMulticenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptorpositive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)Breast Cancer Res Treat2008107879418043897
   PubMed Web of Science ®Google Scholar
• Tubiani HulinMBecetteVBiecheIExemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trialAnticancer Res2007272689269617695434
   PubMed Web of Science ®Google Scholar
• MlineritschBTauschCSingerCExemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)Breast Cancer Res Treat2007 [Epub ahead of print]
   Web of Science ®Google Scholar
• SmithIEDowsettMYapYSAdjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelinesJ Clin Oncol2006242444244716735701
   PubMed Web of Science ®Google Scholar
• DeitcherSRGomesSPThe risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic reviewCancer2004101343944915274057
   PubMed Web of Science ®Google Scholar
• CummingsSRMeltonLJEpidemiology and outcomes of osteoporotic fracturesLancet200235993191761176712049882
   PubMed Web of Science ®Google Scholar
• FisherBConstantinoJPWickerhamDLTamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJ Natl Cancer Inst19989018137113889747868
   PubMed Web of Science ®Google Scholar
• CookeALMetgeCLixLPriorHJLeslieWDTamoxifen use and osteoporotic fracture risk - A population based analysisJ Clin Oncol2008 Epub October 6
   PubMed Web of Science ®Google Scholar
• DingHFieldTSBone health in postmenopausal women with early breast cancer: how protective is tamoxifen?Cancer Treat Rev200733650651317573199
   PubMed Web of Science ®Google Scholar
• ColemanREBanksLMGirgisISSkeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled studyLancet Oncol20078211912717267326
   PubMed Web of Science ®Google Scholar
• KesselBHip fracture prevention in postmenopausal womenObstet Gynecol Surv200459644645515167766
   PubMed Web of Science ®Google Scholar
• MarkopolousCPolychronisAZobolasVThe effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-studyBreast Cancer Res Treat2005931616616184460
   PubMed Web of Science ®Google Scholar
• RutqvistLEJohanssonHLong-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancerActa Oncol200746213314517453361
   PubMed Web of Science ®Google Scholar
• FallowfieldLBlissJPorterLQuality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancerJ Clin Oncol20062491091716484701
   PubMed Web of Science ®Google Scholar
• JonesSECantrellJVukeljaSComparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudyJ Clin Oncol200725304765477117947724
   PubMed Web of Science ®Google Scholar
• DerzkoCElliottSLamWManagement of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapyCurr Oncol200714Suppl 1S20S4018087605
   PubMedGoogle Scholar
• KendallADowsettMFolkerdESmithICaution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitorsAnn Oncol200617458458716443612
   PubMed Web of Science ®Google Scholar
• MokKJuraskovaIFriedlanderMThe impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directionsBreast2008512 [epub ahead of print]
   PubMed Web of Science ®Google Scholar
• PresantCABossermanLYoungTAromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patientsClin Breast Cancer200771077577818021478
   PubMed Web of Science ®Google Scholar
• MoralesLPansSVerschuerenKProspective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndromeJ Clin Oncol2008512 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• CellaDFallowfieldLJRecognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapyBreast Cancer Res Treat2008107216718017876703
   PubMed Web of Science ®Google Scholar
• FrancheschiMScarcelliMNiroVPrevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patientsDrug Saf200831654555618484788
   PubMed Web of Science ®Google Scholar
• CirilloDJWallaceRBWuLYoodRAEffect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health InitiativeArthritis Rheum200654103194312017009251
   PubMed Web of Science ®Google Scholar
• ThomasRWilliamsMMarshallCWalkerLSwitching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant womenBr J Cancer2008981494149918392053
   PubMed Web of Science ®Google Scholar